Pirfenidone: an anti-fibrotic therapy for progressive kidney disease

被引:84
作者
Cho, Monique E. [1 ]
Kopp, Jeffrey B. [1 ]
机构
[1] NIH, Kidney Dis Branch, Bethesda, MD 20892 USA
关键词
fibrosis; glomerulosclerosis; inflammation; proteinuria; renal failure; GROWTH-FACTOR-BETA; IDIOPATHIC PULMONARY-FIBROSIS; BLEOMYCIN-HAMSTER MODEL; CHRONIC CYCLOSPORINE NEPHROTOXICITY; PHASE-II TRIAL; ANTIFIBROTIC AGENT; GENE-EXPRESSION; LUNG FIBROSIS; OPEN-LABEL; TRANSFORMING GROWTH-FACTOR-BETA-1;
D O I
10.1517/13543780903501539
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Importance of the field. Many chronic diseases of various etiologies lead to fibrosis and organ dysfunction. Despite many advances in medicine in recent years, options to slow the progression of fibrotic diseases have remained limited. The recent availability of pirfenidone, an antifibrotic and anti-inflammatory investigational agent, thus offers a new hope for treating progressive fibrotic diseases. Areas covered in this review. This review provides concise review of the available data regarding the mechanism and pharmacokinetics of pirfenidone and preclinical and clinical data regarding efficacy and safety in fibrotic diseases of the kidney. It also reviews results of clinical trials involving pirfenidone in other fibrotic diseases. What the reader will gain: The review will provide in-depth review of pirfenidone with a renal focus. Take home message: Because many of the available clinical trials have been small and/or uncontrolled, conclusive evidence regarding efficacy and safety of pirfenidone is lacking, particularly in patients with renal or hepatic dysfunction. Larger studies are needed to better understand long-term efficacy and safety of this medication in various patient populations.
引用
收藏
页码:275 / 283
页数:9
相关论文
共 57 条
[1]   Pirfenidone in the treatment of primary sclerosing cholangitis [J].
Angulo, P ;
MacCarty, RL ;
Sylvestre, PB ;
Jorgensen, RA ;
Wiesner, RH ;
LaRusso, NA ;
Lindor, KD .
DIGESTIVE DISEASES AND SCIENCES, 2002, 47 (01) :157-161
[2]   Pirfenidone for the treatment of idiopathic pulmonary fibrosis: therapeutic potential prompts further investigation [J].
Antoniu, SA .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2005, 14 (11) :1443-1447
[3]  
Antoniu Sabina A, 2006, Expert Opin Investig Drugs, V15, P823, DOI 10.1517/13543784.15.7.823
[4]   A pilot study in patients with established advanced liver fibrosis using pirfenidone [J].
Armendariz-Borunda, J. ;
Islas-Carbajal, M. C. ;
Meza-Garcia, E. ;
Rincon, A. R. ;
Lucano, S. ;
Sandoval, A. S. ;
Salazar, A. ;
Berumen, J. ;
Alvarez, A. ;
Covarrubias, A. ;
Arechiga, G. ;
Garcia, L. .
GUT, 2006, 55 (11) :1663-1665
[5]   Pirfenidone attenuates ischaemia-reperfusion injury in the rat small intestine [J].
Arumugam, TV ;
Shiels, IA ;
Margolin, SB ;
Taylor, SM ;
Brown, L .
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2002, 29 (11) :996-1000
[6]   Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis [J].
Azuma, A ;
Nukiwa, T ;
Tsuboi, E ;
Suga, M ;
Abe, S ;
Nakata, K ;
Taguchi, Y ;
Nagai, S ;
Itoh, H ;
Ohi, M ;
Sato, A ;
Kudoh, S ;
Raghu, G .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2005, 171 (09) :1040-1047
[7]   Phase II trial of pirfenidone in adults with neurofibromatosis type 1 [J].
Babovic-Vuksanovic, D. ;
Ballman, K. ;
Michels, V. ;
McGrann, P. ;
Lindor, N. ;
King, B. ;
Camp, J. ;
Micic, V. ;
Babovic, N. ;
Carrero, X. ;
Spinner, R. ;
O'Neill, B. .
NEUROLOGY, 2006, 67 (10) :1860-1862
[8]   Phase I trial of pirfenidone in children with neurofibromatosis 1 and plexiform neurofibromas [J].
Babovic-Vuksanovic, Dusica ;
Widemann, Brigitte C. ;
Dombi, Eva ;
Gillespie, Andrea ;
Wolters, Pamela L. ;
Toledo-Tamula, Mary Anne ;
O'Neill, Brian P. ;
Fox, Elizabeth ;
MacDonald, Tobey ;
Beck, Heather ;
Packer, Roger J. .
PEDIATRIC NEUROLOGY, 2007, 36 (05) :293-300
[9]   TRANSFORMING GROWTH FACTOR-BETA-1 INDUCES EXTRACELLULAR-MATRIX FORMATION IN GLOMERULONEPHRITIS [J].
BORDER, WA ;
RUOSLAHTI, E .
CELL DIFFERENTIATION AND DEVELOPMENT, 1990, 32 (03) :425-432
[10]   SUPPRESSION OF EXPERIMENTAL GLOMERULONEPHRITIS BY ANTISERUM AGAINST TRANSFORMING GROWTH FACTOR-BETA-1 [J].
BORDER, WA ;
OKUDA, S ;
LANGUINO, LR ;
SPORN, MB ;
RUOSLAHTI, E .
NATURE, 1990, 346 (6282) :371-374